Sarepta Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Sarepta Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Sarepta Therapeutics Inc Strategy Report
- Understand Sarepta Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Sarepta Therapeutics Inc (Sarepta) discovers and develops unique RNA-targeted medicines to treat rare diseases. The company develops its pipeline products using its multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. The company’s platform is based on its pioneering work with phosphorodiamidate morpholino oligomer (PMO) chemistries. Its commercial products include Exondys 51, Vyondys 53 and Amondys 45 indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene. Its pipeline product includes SRP-9001, SRP-5051, SRP-9003 and SRP-5045 indicated for the treatment of DMD, limb-girdle muscular dystrophies (LGDMs) and other neuromuscular and central nervous system disorders. Sarepta is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
215 1st St Ste 415, Cambridge, Massachusetts, 02142-1213
Website
www.sarepta.com
Telephone
1 617 2744000
No of Employees
1,162
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SRPT (NASD)
Revenue (2022)
$933.0M
32.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-68%
(2022 vs 2021)
Market Cap*
$8.1B
Net Profit Margin (2022)
XYZ
-26.4%
(2022 vs 2021)
* As of and is in US$
Sarepta Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Amondys 45 - Duchenne Muscular Dystrophy | VYONDYS |
| Vyondys 53 - Duchenne Muscular Dystrophy | EXONDYS |
| Exondys 51 - Duchenne Muscular Dystrophy | AMONDYS |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Financing Agreements | In August, the company invested Lexeo in Therapeutics. |
| 2023 | Regulatory Approval | In June, the company announced U.S. Food and Drug Administration accelerated approval of ELEVIDYS (delandistrogene moxeparvovec-rokl), an adeno-associated virus based gene therapy to treat patients with ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD). |
| 2023 | Others | In February, the company announced the official opening of Route 79, The Duchenne Scholarship Program. |
Competitor Comparison
| Key Parameters | Sarepta Therapeutics Inc | Pfizer Inc | Sanofi | Daiichi Sankyo Co Ltd | Nippon Shinyaku Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | Japan | Japan |
| City | Cambridge | New York | Paris | Chuo-Ku | Kyoto-Shi |
| State/Province | Massachusetts | New York | Ile-de-France | Tokyo | Kyoto |
| No. of Employees | 1,162 | 83,000 | 91,573 | 17,435 | 2,186 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Douglas S. Ingram | Director; President; Chief Executive Officer | Executive Board | 2017 | 60 |
| M. Kathleen Behrens, Ph.D. | Chairwoman | Executive Board | 2015 | 70 |
| Ian M. Estepan | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 47 |
| Alison Nasisi | Chief People Officer | Senior Management | 2021 | - |
| Louise Rodino-Klapac, Ph.D | Chief Scientific Officer; Executive Vice President; Head - Research and Development | Senior Management | 2021 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward